T. Ruhstaller

Type de document

Articles (10) Colloques et conférences (3)

Co-auteur

Date

Source

Mot-clé

cancer (12) Treatment (12) Cancer (12) Patients (12) Cancer (12) Patients (12) thérapie (11) procès (11) Therapeutics (11) Breast (11) maladie (9) maladie (9) Chemotherapy (8) Human beings (8) Chemotherapy (8) Control (7) survie (6) Survival (6) Older people (6) toxicité (5) temps (durée) (5) Methods (5) Ci (Chinese poetry) (5) Time (5) Bevacizumab (5) Methods (5) Toxicology (5) dose (4) taux (4) Surgery (4)

Documents écrit par T. Ruhstaller (13) | parle de T. Ruhstaller (0)

Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive Breast Cancer.
W.P. Weber et al. (1 oct. 2023)
Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).
C. Tausch et al.
Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14].
A. Mueller et al.
Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).
W.P. Weber et al.
Oncological care organisation during COVID-19 outbreak.
C.E. Onesti et al.
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.
S. Schmid et al. (10 sept. 2019)
Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients.
S. Cattin et al. (8 mars 2016)
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.
C. Rochlitz et al. (2016)
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06).
C. Rochlitz et al. (2011)
MMP-9 as predictive factor for response and progression free survival in breast cancer patients treated with bevacizumab and pegylated liposomal doxorubicin. A multicenter, single-arm phase II trial (SAKK24/06). On behalf of the Swiss Group for Clinical Cancer Research (SAKK).
K. Zaman et al. (2010)
hMMP9 as predictive factor for response and progression free survival in breast cancer patients treated with bevacizumab and pegylated liposomal doxorubicin (PLD)
K. Zaman et al. (2010)
Can resistance to trastuzumab be reversed by endocrine therapy? Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with ER-positive, HER-2 positive, advanced breast cancer: a proof-of-concept trial (SAKK 23/03)
D. Koeberle et al. (2010)
Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study
Y. Seium et al.